DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Allergan plc
(NYSE: AGN), today announced that its Warner Chilcott and Watson subsidiaries have
reached resolutions with all plaintiffs, including a class of
direct purchasers, individual direct purchasers that previously
opted out of the direct purchaser class, and a class of indirect
purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the
previously disclosed antitrust litigation in the U.S. District
Court for the District of Rhode
Island. The settlements make no admission of
wrongdoing on the part of the company and resolve the litigation
that was scheduled to go to trial on January
6, 2020.
Warner Chilcott and Watson will
pay approximately $300 million under
the settlement agreements. The settlements are subject to court
approval of the agreements with the direct and indirect purchaser
classes.
The company will take a pre-tax GAAP charge
of approximately $300
million to its fourth quarter 2019 earnings.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland, is a global pharmaceutical leader
focused on developing, manufacturing and commercializing branded
pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan
markets a portfolio of leading brands and best-in-class products
primarily focused on four key therapeutic areas including medical
aesthetics, eye care, central nervous system and gastroenterology.
As part of its approach to delivering innovation for better patient
care, Allergan has built one of the broadest
pharmaceutical and device research and development pipelines in the
industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to
working with physicians, healthcare providers and patients to
deliver innovative and meaningful treatments that help people
around the world live longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
About Warner Chilcott and
Watson
Warner Chilcott and Watson
subsidiaries include Warner Chilcott Public Limited Company, Warner
Chilcott Company, Inc., Warner Chilcott Company, LLC, Warner Chilcott (US), LLC, Warner Chilcott
Laboratories Ireland, Limited, Warner Chilcott Holdings Company
III, Ltd., Warner Chilcott Corporation, and Warner Chilcott Sales (US), LLC, (collectively,
"Warner Chilcott") and Watson
Pharmaceuticals, Inc. and Watson Laboratories, Inc. (collectively
"Watson").
In 2013, Watson changed its corporate name to Actavis. The
same year, Warner Chilcott became a
wholly owned subsidiary of Actavis plc which thereafter changed its
corporate name to Allergan.
Contacts
Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7162
Media:
Lisa Brown
(862) 261-7320
View original content to download
multimedia:http://www.prnewswire.com/news-releases/warner-chilcott-and-watson-resolve-antitrust-class-action-litigation-with-direct-and-indirect-purchasers-of-loestrin-24-fe-and-minastrin-24-fe-300981457.html
SOURCE Allergan plc